Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis
- 28 October 2025
- journal article
- review article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2297-2303
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- LBA25 Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)Annals of Oncology, 2024
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyThe Lancet, 2023
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal CancerJAMA, 2023
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7ESMO Open, 2021
- Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 studyInternational Journal of Clinical Oncology, 2020
- GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networksJournal of Clinical Epidemiology, 2019
- Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal CancerJAMA, 2018
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- FTIR spectroscopic, thermal and XRD characterization of hydroxyapatite from new natural sourcesSpectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2011